Unsafe, Not Effective, $3.2 Million Per Dose: Why Is This Drug Still Available?

Forefront Group 2026 Dataset

View at publisher

Authors: Robert M. Kaplan

DOI: 10.1377/forefront.20260202.730447

Cited by: 0

Fields of Study & Subjects

Pharmaceutical Economics and Policy Pharmacovigilance and Adverse Drug Reactions Pharmaceutical industry and healthcare